EHA Launches Clinical Guidelines on Multiple Myeloma and Large B-Cell Lymphoma

The European Hematology Association (EHA) has published two major clinical practice guidelines on multiple myeloma (MM) and large B-cell lymphoma (LBCL), marking  a new milestone in its mission to provide trusted and expert-driven resources for hematology professionals. 

Advancements in clinical practice in MM and LBCL 

EHA has released its first dedicated guideline for large B-cell lymphoma (LBCL), which is the most common form of aggressive lymphoma and represents one-third of adult lymphoma cases.1 This guideline addresses the critical role of PET-CT imaging in risk stratification, staging, and response assessment, while outlining first-line treatment strategies, including the role of R-CHOP and Pola-R-CHP. It also addresses tailored approaches for elderly and frail patients, strategies for central nervous system prophylaxis, and cutting-edge therapies such as CAR-T and bispecific antibodies in relapsed or refractory disease. 

Additionally, EHA has published an updated set of EHA–EMN Clinical Practice Guidelines for the management of smoldering multiple myeloma (SMM) and multiple myeloma (MM) in collaboration with the European Myeloma Network (EMN). The update reflects rapid advancements in treatment, offering guidance on 14 newly approved therapeutic regimens in Europe and the US, novel prognostic factors, and the application of the new international staging system. It also provides practical recommendations for managing myeloma-related complications, such as bone disease and renal impairment, and offers safety guidance for toxicities linked to emerging T-cell–engaging therapies. 

“These new guidelines reflect EHA’s strong commitment to delivering timely, evidence-based resources on clinically complex conditions and emerging therapies,” said Prof. Konstanze Döhner, EHA President. “They are intended to guide physicians in daily practice and to improve both patient outcomes and quality of life.”  

A growing initiative 

Evidence- and consensus-based guidelines are an essential tool for clinicians and define best practices in diagnosis, treatment, and follow-up care. EHA guidelines are developed by leading experts together with patient representatives and place both professional needs and patient outcomes at the center of clinical decision-making. With these publications, EHA reaffirms its role as a primary producer of authoritative member- and patient-centered resources that advance hematology care. 

Since establishing the EHA Guidelines Committee and methodology in 2019, EHA has built a portfolio of guidelines spanning malignant and non-malignant conditions. These guidelines are developed through rigorous processes that integrate multidisciplinary expertise and the perspectives of patients, thus ensuring recommendations are both scientifically sound and clinically relevant. 

Borderless Hematology in action

Through its investment in guideline development, EHA advances its vision of ‘Borderless Hematology’ by fostering knowledge exchange, strengthening a global professional network, and ensuring that care is not restricted by geography. 

“Our guidelines truly embody EHA’s mission: to empower hematology professionals with the knowledge and tools they need to transform patient care,” Prof Döhner added. “Looking ahead to 2026, we remain committed to expand this portfolio further, strengthen educational support, and continue driving innovation across the field of hematology.”  

The majority of guidelines are published in EHA’s open access journal HemaSphere and are also freely accessible via the interactive EHA Guidelines App on the Apple App Store and the Google Play Store.